Angelos Mathew G, Ballard Hatcher J, Barta Stefan K
Department of Medicine, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
J Pers Med. 2022 Feb 11;12(2):267. doi: 10.3390/jpm12020267.
Peripheral T-cell lymphomas (PTCLs) are a rare and heterogenous subset of non-Hodgkin lymphoma characterized by an aggressive clinical course. Historically, the treatment of PTCLs have been analogous to that of aggressive B-cell lymphomas; however, it has been well-established that overall responses and complete remission rates are far inferior using near-identical chemotherapy strategies. Recently, there has been a plethora of newer agents designed to target distinguishing cellular and molecular features of specific PTCL subtypes. These agents have been proven to yield superior anti-lymphoma responses and, in some cases, overall survival in the relapsed, refractory, and frontline treatment setting. In this review, we will summarize and highlight the most influential clinical trials leading to the Food and Drug Administration (FDA) approval of several novel therapeutic agents against PTCL, with an emphasis on emerging studies and strategies to expand their potential use in the frontline treatment setting.
外周T细胞淋巴瘤（PTCL）是一种罕见且异质性的非霍奇金淋巴瘤亚型，其临床病程具有侵袭性。从历史上看，PTCL的治疗方法与侵袭性B细胞淋巴瘤类似；然而，已经明确的是，使用几乎相同的化疗策略时，总体缓解率和完全缓解率要低得多。最近，有大量旨在针对特定PTCL亚型独特细胞和分子特征的新型药物。这些药物已被证明能产生更好的抗淋巴瘤反应，在某些情况下，还能提高复发、难治和一线治疗环境中的总生存率。在这篇综述中，我们将总结并重点介绍导致美国食品药品监督管理局（FDA）批准几种针对PTCL的新型治疗药物的最具影响力的临床试验，重点关注新兴研究和扩大其在一线治疗环境中潜在用途的策略。
